Evidence map›Paper›PMID 30246233›Full record

ArticleEndocrine2018

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide.

D Bengtsson, H D Schrøder, K Berinder, D Maiter, C Hoybye, O Ragnarsson, U Feldt-Rasmussen, Å Krogh Rasmussen, A van der Lely, M Petersson and 3 more

Open access · greenAbstract readLetter
PubMed Publisher
In one paragraph

Article in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.The Journal of clinical endocrinology and metabolism · 2023
    Article
  4. Aggressive corticotroph tumors and carcinomas.Journal of neuroendocrinology · 2022
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Emerging and Novel Treatments for Pituitary Tumors.Journal of clinical medicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 4 countries.

D BengtssonDepartment of Endocrinology, Kalmar, Kalmar County Council and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
H D SchrøderDepartment of Pathology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
K BerinderDepartment of Molecular Medicine and Surgery, Patient Area Endocrinology and Nephrology, Inflammation and Infection Theme, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
D MaiterDepartment of Endocrinology and Nutrition, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium.
C HoybyeDepartment of Molecular Medicine and Surgery, Patient Area Endocrinology and Nephrology, Inflammation and Infection Theme, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
O RagnarssonDepartment of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg and Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.
U Feldt-RasmussenDepartment of Medical Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Å Krogh RasmussenDepartment of Medical Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
A van der LelyDepartment of Medicine, Division of Endocrinology, Erasmus University, Rotterdam, The Netherlands.
M PeterssonDepartment of Molecular Medicine and Surgery, Patient Area Endocrinology and Nephrology, Inflammation and Infection Theme, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
G JohannssonDepartment of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg and Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.
M AndersenDepartment of Endocrinology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
P BurmanDepartment of Endocrinology, Skåne University Hospital, University of Lund, Malmo, Sweden. pia.burman@med.lu.se.
Karolinska Institutet · SERigshospitalet · DKUniversity of Southern Denmark · DKErasmus University Rotterdam · NLLinköping University · SESahlgrenska University Hospital · SESkåne University Hospital · SEUCLouvain · BEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntineoplastic Agents, AlkylatingDNA Modification MethylasesDNA Repair EnzymesFemaleHumansMaleMiddle AgedPituitary NeoplasmsPrognosisSurvival RateTemozolomideTreatment OutcomeTumor Suppressor ProteinsAntineoplastic Agents, AlkylatingDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanTemozolomideTumor Suppressor Proteins

Identifiers

PMID30246233
OpenAlexW2893824347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.